Cohance Lifesciences Limited (BOM:543064)

Market Cap	264.37B
Revenue (ttm)	12.59B
Net Income (ttm)	2.41B
Shares Out	n/a
EPS (ttm)	9.40
PE Ratio	109.53
Forward PE	42.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	363,495
Average Volume	63,644
Open	700.15
Previous Close	707.50
Day's Range	700.15 - 714.60
52-Week Range	700.15 - 1,359.00
Beta	n/a
RSI	19.17
Earnings Date	Nov 12, 2025

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.